Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to demonstrate that treatment with a 6-monthly injection of hormone therapy is as good and as well tolerated as the standard 3-monthly hormone therapy injections available for treating prostate cancer. The study will also aim to answer whether both doctors and patients would prefer treatment with a 6-monthly injection rather than injections every 3 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
In addition:
For patients with locally advanced prostate cancer (M0), LHRH agonist injection (any formulation) must have been initiated within the last 3 years from Baseline,
For patients with metastatic prostate cancer (M+) and a Gleason score
≤ 7, LHRH agonist injection (any formulation) must have been initiated within the last 2 years from Baseline,
For patients with metastatic prostate cancer (M+) and a Gleason score > 7, LHRH agonist injection (any formulation) must have been initiated within the last 12 months from Baseline.
Patients must have an estimated life expectancy of at least twelve months according to the investigator's assessment.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
27 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal